Zelluna’s mission is to eliminate solid cancers by unleashing the most powerful elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies. The team comprises experienced biotech entrepreneurs that have taken immune-oncology projects from inception through to the clinic and supported by a highly experienced international board.
Zelluna is committed to provide benefit to patients, their families and all those around them, by developing therapies that bring together TCR guidance with the effector functions of allogeneic NK cells (TCR-NK) deploying a mechanism of action that has the potential to be both safe and potent. This platform has unique advantages providing “off-the-shelf” access to an advanced therapy for large patient populations.
Zelluna is pioneering a novel therapeutic approach and holds itself to lofty ambitions. To enable this, Zelluna believes in working deliberately on its culture to unleash the fullest extent of the potential of the people by nurturing individual growth and teams through the “Zelluna Academy”. The Zelluna Academy was established to represent the various programs and activities intended to support continuous learning and development for individuals and teams across the organisation.
Zelluna Immunotherapy AS was established in 2016 and is headquartered at the Oslo Cancer Cluster Innovation Park in Oslo, Norway. In March 2025 Zelluna Immunotherapy AS combined its business with Ultimovacs ASA to form Zelluna. The prime focus of Zelluna is to develop novel TCR-NK therapies for treatment of solid cancers and the company is a public limited liability company listed on the Oslo Stock Exchange in Norway (OSE: ZLNA).
